Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12100341 | 0.87 | KDM4E (0.60) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664175 | 0.82 | MAPK14 (0.63) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664162 | 0.81 | MEN1 (0.51) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664179 | 0.81 | MAPT (0.50) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664215 | 0.81 | ALDH1A1 (0.56) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664196 | 0.81 | MAPK14 (0.50) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664177 | 0.81 | MAPT (0.50) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL14304403 | 0.81 | KMT2A (0.48) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13664210 | 0.80 | MAPT (0.49) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL13664191 | 0.80 | MAPK14 (0.48) | MAPTKMT2AMEN1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | MAPT 4701/4885KMT2A 3722/4885MEN1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.